← Research library

Slow-injection thymopentin versus placebo in active rheumatoid arthritis

Randomized study in people · 1985

What was studied
41 randomized participants with active rheumatoid arthritis, 21 thymopentin and 20 placebo.
Main finding
Between-group clinical findings · At week three, thymopentin performed better than placebo on joint tenderness, swelling, pain on awakening and overall disease activity.

Reported findings and study design

Reported findings

Double-blind comparison of 50 mg IV in divided pushes over 10 minutes, three times weekly for three weeks. The control arm received placebo in the same way. Follow-up continued four weeks after treatment.

Population or model 41 randomized participants with active rheumatoid arthritis, 21 thymopentin and 20 placebo.

Dose, route and schedule

Double-blind comparison of 50 mg IV in divided pushes over 10 minutes, three times weekly for three weeks. The control arm received placebo in the same way. Follow-up continued four weeks after treatment.

Protocol source ↗ · Original indexed abstract and Lancet opening page. The full archive copy requires access.

Results · Original indexed abstract and Lancet opening page. The full archive copy requires access.
MeasureResultComparison, timing and statistics
Between-group clinical findingsAt week three, thymopentin performed better than placebo on joint tenderness, swelling, pain on awakening and overall disease activity.
Other measures and follow-upLeft-hand grip did not improve on thymopentin. Placebo improved morning stiffness within the group. Some improvement persisted at four weeks off treatment, with a trend toward relapse.
Laboratory markers and safetyNo significant changes in tested laboratory measures. Both arms reported minor side effects.

Absolute group means and adverse-event counts are unavailable in the accessible pages. The 1984 interim and 1985 supplement reports match the same 21/20 arms, dosing and endpoints. Together the three reports contribute one 41-person cohort.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • Absolute group means and adverse-event counts are unavailable in the accessible pages. The 1984 interim and 1985 supplement reports match the same 21/20 arms, dosing and endpoints. Together the three reports contribute one 41-person cohort.

Related publications may describe some of the same participants or experiments.

Source details

Original indexed abstract and Lancet opening page. The full archive copy requires access.

Sources checked

Added to the library

Citation

Randomized trialEnglish abstract

M. G. Malaise, C. Hauwaert, P. Franchimont, B. Danneskiold-Samsoe, R. Bach-Andersen, D. Gross, H. Gerber, H. Gerschpacher, H. Stocker, K. Bolla. Slow-injection thymopentin versus placebo in active rheumatoid arthritis The Lancet 1(8433), 832–836

Study source ↗ · DOI 10.1016/S0140-6736(85)92205-6 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards